Changes in the oral intake of phosphorus could induce the reported changes in the serum concentration of 1,25-dihydroxyvitamin D (1,25-(OH)2D) by inducing changes in its production rate (PR) or metabolic clearance rate (MCR), or both. To investigate these possibilities, we employed the constant infusion equilibrium technique to measure the PR and MCR of 1,25-(OH)2D in six healthy men in whom the oral intake of phosphorus was initially maintained at 1,500 mg/70 kg body weight per d for 9 d, then restricted to 500 mg/d (coupled with oral administration of aluminum hydroxide) for 10 d, and then supplemented to 3,000 mg/d for 10 d. With phosphorus restriction, the serum concentration of 1,25-(OH)2D increased by 80% from a mean of 38±3 to 68±6 pg/ml, P < 0.001; the PR increased from 1.8±0.2 to 3.8±0.6 tg/d, P < 0.005; the MCR did not change significantly. The fasting serum concentration of phosphorus decreased from 3.5±0.2 to 2.6±0.2 mg/dl, P < 0.01. With phosphorus supplementation, the serum concentration of 1,25-(OH)2D decreased abruptly, reaching a nadir within 2 to 4 d; after 10 d of supplementation, the mean concentration of 27±4 pg/ml was lower by 29%, P < 0.01, than the value measured when phosphorus intake was normal. The PR decreased to 1.3±0.2 jg/d, P < 0.05; the MCR did not change significantly.
Introduction 1,25 dihydroxyvitamin D3 (1,25-(OH)2D3) is the metabolite of vitamin D currently considered to be the most biologically active with respect to enhancement of bone resorption and intestinal absorption of calcium and phosphorus (1) (2) (3) (4) . The renal synthesis of 1,25-(OH)2D3 from its endogenous precursor, 25-hydroxyvitamin D3, is catalyzed by 25-hydroxyvitamin D3-la-hydrox-by parathyroid hormone (PTH) (9) (10) (11) (12) (13) (14) (15) and suppressed by 1,25-(OH)2D (11, 13, 14) , normal vitamin D status (15) , and some function of the dietary intake ofinorganic phosphorus (16) , perhaps through an effect on its plasma concentration (12, 17) .
Restriction of dietary phosphorus can induce an increase in the serum concentration of 1,254OH)2D in normal men and women (18) (19) (20) (21) and in children with moderate renal insufficiency (22) . Conversely, in patients with idiopathic hypercalciuria (23) or primary hyperparathyroidism (24) , supplementation ofphosphorus can induce a decrease in the serum concentration of 1,25-(OH)2D from supernormal to normal levels. It has been inferred that these phosphorus-induced changes in serum concentration of 1 ,25-OH)2D reflect changes in the rate of its renal production, because in the chick and rat, restriction of dietary phosphorus can increase both the activity ofrenal I -hydroxylase (16) and the synthetic rate of 1,25-(OH)2D3 (25, 26) , when measured in vitro. But in a preliminary report, phosphorus restriction in the rat induced not only an increase in the plasma concentration of 1 ,25-(OH)2D, but also a doubling of the plasma halflife of intravenously administered 3H-1 ,254OH)2D, suggesting that a decrease in the metabolic clearance rate (MCR) of the hormone contributed to the increase in its plasma concentration (27) . Indeed, in some metabolic circumstances, a change in the plasma concentration of a steroid hormone can be accounted for, at least in part, by a change in its MCR (28) (29) (30) (31) . Thus, phosphorus-induced changes in the serum concentration of 1,25-(OH)2D might result from changes in its MCR, as well as from changes in its production rate (PR). Employing the infusion equilibrium technique, we measured these rates in healthy men after restriction and supplementation of their oral intake of phosphorus had induced clear cut and persisting increases and decreases, respectively, in the serum concentration of 1,25-(OH)2D. We find that changes in the PR of 1,2540-H)2D account entirely for the phosphorus-induced changes in serum concentration of this hormone.
Methods
We determined the effect of restriction, then supplementation, of the 26, 27 (n)-3H-vitamin D3 (3H-I,25-(OH)2D3) (158 Ci/mmol, Amersham Corp., Arlington Heights, IL) in 0.5 ml absolute ethanol were solubilized in a 10-ml sterile aliquot of the patients own serum, the latter dispersed in 0.9% NaCl, and the solution infused intravenously at aconstant rate of0.193 ml/min (-4,000 dpm/min) (Harvard Apparatus Co., Inc., S. Natick, MA). To assess the possibility that isotope might stick to the infusion apparatus (glass syringe and plastic tubing) during the 20-h period of infusion, we measured counts of 3H in aliquots of solution taken at the time isotope was prepared for infusion, and from the syringe and end of the plastic tubing at completion of the infusion some 21 h later. We found no evidence of significant sticking of isotope to the infusion apparatus during the period of infusion. In preliminary studies, we determined that stable serum concentrations of 3H-1 ,25-(OH)2D3 were attained and maintained after 16 to 18 h of constant infusion of radiolabeled hormone. In subsequent studies, radiolabeled hormone was infused for 20 h; during the final 3-h equilibrium period, blood was drawn at 30-min intervals for measurement of serum concentrations of both tritiated and endogenous 1,25-(OH)2D. The total amount of 3H-1,25-(OH)2D administered over 20 h was -0.005 ug, or 0.3% of the estimated daily renal production of the hormone.
Laboratory methods
Measurement of 3H-I1,25-(OH)2D in serum. Approximately 100 ng of chromatographically purified 1,25-(OH)2D3, kindly provided by Hoffman-La Roche, Inc., Nutley, NJ, in 20 al of ethanol were added to each 2.0-ml serum sample to determine percentage of recovery. The serum was extracted twice with peroxide free diethyl ether (3:1, vol/vol), and the extract applied to a silica Sep-pak (Waters Inc., Milford, MA) in a solvent system of0.1% isopropanol and 99.9% hexane. The Sep-pak was washed sequentially, first with 10 ml of isopropanol/hexane (2.5:97.5) and then with 7.5 ml of isopropanol/dichloromethane (4:96). 1,25-dihydroxyvitamin D was then eluted with 10 ml of isopropanol dichloromethane (10:90). The fraction was dried under N2, resolubilized and applied to a radial compression separation system (Waters Inc.) using an 8-mm Si radial compression column (particle size, 5 1A) in a solvent system of isopropanol/hexane (8:92) at a flow rate of 4.5 ml/min. The content of 3H-1,25-(OH)2D in the collected fraction was determined by direct scintillation counting. Recovery of 1,25-(OH)2D3 added to the serum was accomplished by comparison of the ultraviolet absorbance maximum at 254 nm of the sample to that of a series of crystalline standards of I,25-(OH)2D3. Recovery of 1 ,25-(OH)2D3 added to serum was 65-70%. Intraassay coefficient of variation of 3H-1,25-(OH)2D in serum was 6.8% at a tritium concentration of 150 dpm/ml.
To investigate whether tritiated metabolites of vitamin D other than 3H-I,25-(OH)2D might be detected by our analytical procedures, preliminary studies were performed in which the concentration of 3H-1,25-(OH)2D during equilibrium was measured using two different chromatographic procedures, straight-phase high pressure liquid chromatography (HPLC) as described, and a combination of reverse-phase followed by straight-phase HPLC. In one subject, a large volume of blood was obtained during infusion equilibrium and the serum aliquoted into 10 2.0-ml fractions. Approximately 100 ng of 1,25-(OH)2D3 were added to each 2.0-ml sample, the serum extracted twice with diethyl ether, and the extract applied to a silica Sep-pack, as described. Five ofthe fractions containing 1,25-(OH)2D were chromatographed using the HPLC procedure described. The other five fractions were applied first to a reversephase HPLC system using a uBondapak C 18 column (Waters Inc.) in a solvent system of water/methanol (25:75) at a flow rate of 2.0 ml/min, and then rechromatographed using the straight-phase radial compression separation system (Waters Inc.), as described. intraassay coefficients of variation of 1,25-OH)2D in serum were 13.4 and 12.6%, respectively, at a serum concentration of 31 pg/ml.
Serum concentrations of 25-OHD were measured as previously described (22) . Serum concentrations of iPTH were measured by radioimmunoassay using two antisera: GP-IM, which has high affinity for PTH (1-84) and the midregion ofthe hormone, PTH (44-68), but low affinity for PTH , referred to hereafter as midregion-iPTH (M-iPTH), and CH-12M, which has high affinity for PTH , at least a 30-fold lower affinity for PTH Urinary phosphorus, calcium, and magnesium. Urinary excretion of phosphorus decreased and increased rapidly in response to the decrease and increase, respectively, in phosphorus intake (Table II) ; renal adaptation was essentially complete within 48 h of either maneuver. Urinary excretion of calcium increased immediately and progressively after phosphorus was restricted, and after 10 d had increased by about threefold. After 10 d of phosphorus supplementation, calcium excretion was slightly but significantly lower than the control value. The changes from control (normal phosphorus intake) in urinary excretion of calcium induced by restriction and supplementation of phosphorus varied directly and significantly with the changes from control induced in serum concentration of 1,25-(OH)2D, when the values in the six subjects were analyzed as a single set (r = 0.91, P < 0.001). Changes in urinary excretion ofmagnesium were similar in direction to, but of a lesser magnitude than, those of urinary calcium.
Discussion
The results of the present study confirm that in normal adult subjects (18-21) , as in children with moderate renal insufficiency (22) , restriction of the oral intake of phosphorus combined with ingestion of aluminum hydroxide induces an increase in the serum concentration of 1,25-(OH)2D. When phosphorus was restricted for 10 d, the serum concentration of 1,25-(OH)2D increased immediately and progressively, and within a week, reached a stable maximal value almost twice the value when phosphorus intake was normal (Fig. 1) . The pattern of the increase in serum concentration of 1,25-(OH)2D induced by phosphorus restriction is like that previously observed in healthy adult subjects (19) (20) (21) , although the magnitude of the increase we observed (80%) is greater than that reported to occur after either 4, 10, or 18 d of phosphorus restriction (29, 46 , 32%, respectively) (19) (20) (21) . It seems likely that the greater increase in serum 1,25-(OH)2D observed in the present study reflects a more severe restriction of dietary phosphorus (19, 21) , and possibly also differences in the sex and age of study subjects (20) .
The results of the present study demonstrate that in healthy men, supplementation ofdietary phosphorus induces a decrease in the serum concentration of 1,25-(OH)2D. When phosphorus was supplemented for 10 d (after its restriction), the serum concentration of 1,25-(OH)2D decreased from a maximal value of 68 pg/ml to a nadir of -15 pg/ml within 2 d; thereafter, the concentration increased somewhat to attain a near constant value 60% lower than that obtaining with phosphorus restriction, and -30% lower than the value obtaining with normal phosphorus intake. These findings demonstrate that in man, persisting changes in the oral intake of phosphorus can induce rapidly occurring, large, inverse, and persisting changes in the serum concentration of 1,25-(OH)2D.
We employed the isotope infusion equilibrium technique to determine whether the phosphorus-induced changes in serum concentration of 1,25-(OH)2D reflected changes in its PR or MCR, or both. When phosphorus intake was normal, 1,500 mg/ d, the MCR of 1,25-(OH)2D was estimated to be 34±2 ml/min in the six subjects. We have previously reported that in healthy men, the endogenous serum concentration of 1,25-(OH)2D varies by <20% during a 24-h period (38) ; in the present study the concentration of endogenous hormone was virtually constant during the 3-h infusion equilibrium period. Hence, the PR of 1,25-(OH)2D can be reliably estimated from measurements of MCR and serum concentration of endogenous hormone; the mean value for production rate was 1.8±0.2 ,ug/d. In each of the six subjects studied, the individual values for MCR and PR were clustered tightly about their respective mean values. These mean values are in good agreement with those reported in normal adult subjects, as determined by the equilibrium infusion technique (31) , and are similar to (39) or somewhat higher than (40, 41) those determined by the bolus injection technique. When phosphorus was restricted and then supplemented, the observed increase and decrease in serum concentration of 1,25-(OH)2D was associated with an increase and decrease, respectively, in the PR of the hormone, but not with a significant change in its MCR. Thus, these findings demonstrate that in healthy men, changes in the PR of 1,25-(OH)2D account entirely for the phosphorus-induced changes in serum concentration of this hormone. The present findings accord with studies in the intact chick and rat in which phosphorus restriction increased the activity of 1-hydroxylase ( 16) and the synthetic rate of 1,25-(OH)2D (25, 26) , when measured in vitro in renal cortical tissue. The present studies are also consistent with previous studies in phosphorus-deprived healthy men in whom the rate of disappearance of radiolabeled 25-OH-D3 from plasma was increased, 
